Standardized classification unsuitable for spontaneous reporting: the example of osteonecrosis of the jaw

Bibliography

• Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc Mayo Clin 2008;83:1032–45
   PubMed Web of Science ®Google Scholar
• Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115–17
   PubMed Web of Science ®Google Scholar
• Ruggiero SL, Mehrotra B, Rosenberg TJ, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527–34
   PubMed Web of Science ®Google Scholar
• Germain ML, Herlem E, Herment N, et al. Osteonecrosis of the jaw in a patient with bisphosphonates therapy. Drug Saf 2005;28:956
   Web of Science ®Google Scholar
• Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws. J Oral Maxillofac Surg 2007;65:369–76
   PubMed Web of Science ®Google Scholar
• Ruggiero SL, Dodson TB, Assael LA, et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update. J Oral Maxillofac Surg 2009;67:2–12
   PubMed Web of Science ®Google Scholar
• Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update. J Oral Maxillofac Surg 2014;72:1938–56
   PubMed Web of Science ®Google Scholar
• Schiodt M, Reibel J, Oturai P, et al. Comparison of nonexposed and exposed bisphosphonate-induced osteonecrosis of the jaws: a retrospective analysis from the Copenhagen cohort and a proposal for an updated classification system. Oral Pathol Oral Radiol 2014;117:204–13
   PubMed Web of Science ®Google Scholar
• Moore N, Kreft-Jais C, Haramburu F, et al. Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database. Br J Clin Pharmacol 1997;44:513–18
   PubMed Web of Science ®Google Scholar
• Gahr M, Freudenmann RW, Hiemke C, et al. Abuse of methylphenidate in Germany: data from spontaneous reports of adverse drug reactions. Psychiatry Res 2014;215:252–4
   PubMed Web of Science ®Google Scholar
• Moore N, Paux G, Begaud B, et al. Adverse drug reaction monitoring: doing it the french way. Lancet 1985;326:1056–8
   Google Scholar
• European Medicines Agency. Guideline on good pharmacovigilance practices: Module VI - Management and reporting of adverse reactions to medicinal products. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/02/WC500123203.pdf [Last accessed 1 April 2015]
   Google Scholar
• Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf Int J Med Toxicol 1999;20:109–17
   Google Scholar
• Council for International Organizations of Medical Sciences. CIOMS Form I. Available from: http://cioms.ch/index.php/cioms-form-i [Last accessed 1 April 2015]
   Google Scholar
• US Food and Drug Administration. Reporting serious problems to FDA. What is a serious adverse event? Available from: http://www.fda.gov/safety/medwatch/howtoreport/ucm053087.htm [Last accessed 1 April 2015]
   Google Scholar
• Adami S, Baroni MC, Broggini M, et al. Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin. Osteoporos Int 1993;33:21–7
   Google Scholar
• Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001;19:558–67
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. ODS postmarketing safety review. Available from: http://www.fda.gov/ohrms/dockets/ac/05/briefing/2005-4095B2_03_04-FDA-TAB3.pdf [Last accessed 1 April 2015]
   Google Scholar
• Coleman R, Woodward E, Brown J, et al. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01–04) for women with stage II/III breast cancer. Breast Cancer Res Treat 2011;127:429–38
   PubMed Web of Science ®Google Scholar
• Coleman R, Marshall H, Cameron D, et al. Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 2011;365:1396–405
   PubMed Web of Science ®Google Scholar
• Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23:8580–7
   PubMed Web of Science ®Google Scholar
• O Hoff A, Toth BB, Altundag K, et al. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008;23:826–36
   PubMed Web of Science ®Google Scholar
• Fedele S, Bedogni G, Scoletta M, et al. Up to a quarter of patients with osteonecrosis of the jaw associated with antiresorptive agents remain undiagnosed. Br J Oral Maxillofac Surg 2015;53:13–17
   PubMed Web of Science ®Google Scholar
• Yarom N, Fedele S, Lazarovici TS, et al. Is exposure of the jawbone mandatory for establishing the diagnosis of bisphosphonate-related osteonecrosis of the jaw? J Oral Maxillofac Surg 2010;68:705
   PubMed Web of Science ®Google Scholar
• Junquera L, Gallego L. Nonexposed bisphosphonate-related osteonecrosis of the jaws: another clinical variant? J Oral Maxillofac Surg 2008;66:1516–17
   PubMed Web of Science ®Google Scholar
• Otto S, Abu-Id MH, Fedele S, et al. Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: Not just a sporadic coincidence – a multi-centre study. J Cranio-Maxillofac Surg 2011;39:272–7
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Kosmidis P, Marinis F, et al. Zoledronic acid in patients with stage IIIA/B NSCLC: results of a randomized, phase III study. Ann Oncol 2012;23:2082–7
   PubMed Web of Science ®Google Scholar
• Smith MR, Saad F, Coleman R, et al. Denosumab and bone metastasis-free survival in men with castration-resistant prostate cancer: results of a global phase 3, randomised, placebo-controlled trial. Lancet 2012;379:39–46
   PubMed Web of Science ®Google Scholar
• Fizazi K, Carducci M, Smith M, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011;377:813–22
   PubMed Web of Science ®Google Scholar
• Stopeck AT, Lipton A, Body J-J, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010;28:5132–9
   PubMed Web of Science ®Google Scholar